Potent irreversible DprE1 inhibitor (MIC value <0.19 ng/mL and <0.004 µM against M. tuberculosis H37Ra) with improved stability against nitroreductase metabolism, and good efficacy at lower concentrations in the murine model of chronic tuberculosis (TB); an attractive drug candidate to treat TB in humans. The combination of PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease.

KEYWORDS: PBTZ169 | supplier | DprE1 inhibitor | PBTZ-169 | PBTZ 169 | CAS [1377239-83-2] | DPR | DprE | tuberculosis | TB | mycobacterium | flavo-enzyme | cell wall | biosynthesis | benzothiazinone | epimerase | Decaprenylphosphoryl-beta-D-ribofuranose